Familial Parkinson disease mutations influence α-Synuclein assembly

Neurobiology of Disease

Volumn 43, Issue 3, 2011, Pages 715-724

  Ono, Kenjiro ^a   Ikeda, Tokuhei ^a   Takasaki, Jun ichi ^a   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Synuclein; Atomic force microscopy; Electron microscopy; Mutations; Oligomers; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DIRECT YELLOW 7; MUTANT PROTEIN; OLIGOMER; REAGENT; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; ATOMIC FORCE MICROSCOPY; CIRCULAR DICHROISM; CONTROLLED STUDY; ELECTRON MICROSCOPY; FAMILIAL DISEASE; FAMILIAL PARKINSON DISEASE; LIGHT IRRADIANCE; MUTATION; NUCLEATION ACTIVITY; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; GENES, DOMINANT; HUMANS; LEWY BODY DISEASE; MICROSCOPY, ATOMIC FORCE; MOLECULAR SEQUENCE DATA; PARKINSON DISEASE; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY;

EID: 79960260042     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.05.025     Document Type: Article

References (63)

1. Alim M.A., et al. Tubulin seeds α-Synuclein fibril formation. J. Biol. Chem. 2002, 277:2112-2117.
2. Baba M., et al. Aggregation of α-Synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152:879-884.
3. Bertoncini C.W., et al. Familial mutants of α-Synuclein with increased neurotoxicity have a destabilized conformation. J. Biol. Chem. 2005, 280:30649-30652.
4. Bertoncini C.W., et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured α-Synuclein. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1430-1435.
5. Bitan G., Teplow D.B. Rapid photochemical cross-linking-a new tool for studies of metastable, amyloidogenic protein assemblies. Acc. Chem. Res. 2004, 37:357-364.
6. Bitan G., et al. Amyloid β-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem. 2001, 276:35176-35184.
7. Brown D.R. Oligomeric α-Synuclein and its role in neuronal death. IUBMB Life 2010, 62:334-339.
8. Bussell R., Eliezer D. Residual structure and dynamics in Parkinson's disease-associated mutants of α-Synuclein. J. Biol. Chem. 2001, 276:45996-46003.
9. Chartier-Harlin M.C., et al. α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
10. Conway K.A., et al. Accelerated in vitro fibril formation by a mutant α-Synuclein linked to early-onset Parkinson disease. Nat. Med. 1998, 4:1318-1320.
11. Conway K.A., et al. Fibrils formed in vitro from α-Synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000, 39:2552-2563.
12. Conway K.A., et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-Synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:571-576.
13. Danzer K.M., et al. Different species of α-Synuclein oligomers induce calcium influx and seeding. J. Neurosci. 2007, 27:9220-9232.
14. Davidson W.S., et al. Stabilization of α-Synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998, 273:9443-9449.
15. Dedmon M.M., et al. Heat shock protein 70 inhibits α-Synuclein fibril formation via preferential binding to prefibrillar species. J. Biol. Chem. 2005, 280:14733-14740.
16. Duda J.E., et al. Neuropathology of synuclein aggregates. J. Neurosci. Res. 2000, 61:121-127.
17. Eliezer D., et al. Conformational properties of α-Synuclein in its free and lipid-associated states. J. Mol. Biol. 2001, 307:1061-1073.
18. Evans K.C., et al. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:763-767.
19. Fancy D.A., Kodadek T. Chemistry for the analysis of proteiβ-protein interactions: rapid and efficient cross-linking triggered by long wavelength light. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6020-6024.
20. Fancy D.A., et al. Scope, limitations and mechanistic aspects of the photo-induced cross-linking of proteins by water-soluble metal complexes. Chem. Biol. 2000, 7:697-708.
21. Farrer M., et al. Comparison of kindreds with parkinsonism and α-Synuclein genomic multiplications. Ann. Neurol. 2004, 55:174-179.
22. Fredenburg R.A., et al. The impact of the E46K mutation on the properties of α-Synuclein in its monomeric and oligomeric states. Biochemistry 2007, 46:7107-7118.
23. Fuchs J., et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007, 68:916-922.
24. Fujiwara H., et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
25. Giasson B.I., et al. Mutant and wild type human α-Synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 1999, 274:7619-7622.
26. Giehm L., et al. Low-resolution structure of a vesicle disrupting α-Synuclein oligomer that accumulates during fibrillation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3246-3251.
27. Goldberg M.S., Lansbury P.T. Is there a cause-and-effect relationship between α-Synuclein fibrillization and Parkinson's disease?. Nat. Cell Biol. 2000, 2:E115-E119.
28. Greenbaum E.A., et al. The E46K mutation in α-Synuclein increases amyloid fibril formation. J. Biol. Chem. 2005, 280:7800-7807.
29. Groenning M. Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status. J. Chem. Biol. 2009, 3:1-18.
30. Ibanez P., et al. Causal relation between α-Synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
31. Karpinar D.P., et al. Pre-fibrillar α-Synuclein variants with impaired β-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 2009, 28:3256-3268.
32. Kim H.Y., et al. Structural properties of pore-forming oligomers of α-Synuclein. J. Am. Chem. Soc. 2009, 131:17482-17489.
33. Kruger R., et al. Ala30Pro mutation in the gene encoding α-Synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
34. LeVine H. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993, 2:404-410.
35. LeVine H. Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999, 309:274-284.
36. Li J., et al. Conformational behavior of human α-Synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology 2002, 23:553-567.
37. Lindersson E.K., et al. α-Synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport 2004, 15:2735-2739.
38. Lindersson E., et al. p25α stimulates α-Synuclein aggregation and is co-localized with aggregated α-Synuclein in α-Synucleinopathies. J. Biol. Chem. 2005, 280:5703-5715.
39. Liu I.H., et al. Agrin binds α-Synuclein and modulates α-Synuclein fibrillation. Glycobiology 2005, 15:1320-1331.
40. Markopoulou K., et al. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease. Acta Neuropathol. 2008, 116:25-35.
41. Naiki H., Nakakuki K. First-order kinetic model of Alzheimer's β-amyloid fibril extension in vitro. Lab. Invest. 1996, 74:374-383.
42. Narhi L., et al. Both familial Parkinson's disease mutations accelerate α-Synuclein aggregation. J. Biol. Chem. 1999, 274:9843-9846.
43. Nishie M., et al. Accumulation of phosphorylated α-Synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. 2004, 107:292-298.
44. Nishioka K., et al. Clinical heterogeneity of α-Synuclein gene duplication in Parkinson's disease. Ann. Neurol. 2006, 59:298-309.
45. Okochi M., et al. Constitutive phosphorylation of the Parkinson's disease associated α-Synuclein. J. Biol. Chem. 2000, 275:390-397.
46. Ono K., Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for α-Synuclein fibrils in vitro. J. Neurochem. 2006, 97:105-115.
47. Ono K., et al. α-Synuclein assembly as a therapeutic target of Parkinson's disease and related disorders. Curr. Pharm. Des. 2008, 14:3247-3266.
48. Ono K., et al. Structure-neurotoxicity relationships of amyloid β-protein oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14745-14750.
49. Ono K., et al. Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid β-protein assembly and toxicity. J. Biol. Chem. 2010, 285:23186-23197.
50. Outeiro T.F., et al. Formation of toxic oligomeric α-Synuclein species in living cells. PLoS One 2008, 3:e1867.
51. Polymeropoulos M.H., et al. Mutation in the α-Synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
52. Pronin A.N., et al. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 2000, 275:26515-26522.
53. Rospigliosi C.C., et al. E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in α-Synuclein. J. Mol. Biol. 2009, 388:1022-1032.
54. Seidel K., et al. First appraisal of brain pathology owing to A30P mutant α-Synuclein. Ann. Neurol. 2010, 67:684-689.
55. Singleton A.B., et al. α-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
56. Spillantini M.G., et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6469-6473.
57. Uversky V.N. Neuropathology, biochemistry, and biophysics of α-Synuclein aggregation. J. Neurochem. 2007, 103:17-37.
58. Uversky V.N., et al. Evidence for a partially folded intermediate in α-Synuclein fibril formation. J. Biol. Chem. 2001, 276:10737-10744.
59. Volles M.J., Lansbury P.T. Vesicle permeabilization by protofibrillar α-Synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002, 41:4595-4602.
60. Wood S.J., et al. α-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 1999, 274:19509-19512.
61. Wright J.A., et al. Unique copper-induced oligomers mediate α-Synuclein toxicity. FASEB J. 2009, 23:2384-2393.
62. Yonetani M., et al. Conversion of wild-type α-Synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J. Biol. Chem. 2009, 284:7940-7950.
63. Zarranz J.J., et al. The new mutation, E46K, of α-Synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.